NCT06677892 A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium
| NCT ID | NCT06677892 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Takeda |
| Condition | Cytomegalovirus (CMV) |
| Study Type | OBSERVATIONAL |
| Enrollment | 75 participants |
| Start Date | 2025-02-24 |
| Primary Completion | 2026-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 75 participants in total. It began in 2025-02-24 with a primary completion date of 2026-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cytomegalovirus (CMV) is a common virus that infects many people. It can cause serious illness in people with weak immune systems especially in those undergoing transplants. Maribavir is a medicine approved for treating CMV infection in adults after transplant. The main aim of this study is to check the use of maribavir and learn how safe and effective in treating adults with CMV infection after transplant in Belgium in line with the Belgian reimbursement criteria. During the study, a participant's data will be collected for 2 years. The study does not have fixed visits to the hospital, but it is recommended collect data from routine visits and contacts.
Eligibility Criteria
Inclusion Criteria: * Participant signed an informed consent form. * Aged greater than or equal to (\>=) 18 years at the time of consent. * Received an HSCT/SOT. * Diagnosed with CMV infection/disease any time after the HSCT/SOT date. * Starting maribavir for the first time and in line with the Belgian reimbursement criteria. Exclusion Criteria: • Participant treated with maribavir before the start of the study.
Contact & Investigator
Study Director
STUDY DIRECTOR
Takeda
Frequently Asked Questions
Who can join the NCT06677892 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cytomegalovirus (CMV). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06677892 currently recruiting?
Yes, NCT06677892 is actively recruiting participants. Contact the research team at medinfoUS@takeda.com for enrollment information.
Where is the NCT06677892 trial being conducted?
This trial is being conducted at Anderlecht, Belgium, Anderlecht, Belgium, Brussels, Belgium, Edegem, Belgium and 5 additional locations.
Who is sponsoring the NCT06677892 clinical trial?
NCT06677892 is sponsored by Takeda. The principal investigator is Study Director at Takeda. The trial plans to enroll 75 participants.